Abstract
In advanced non-small cell lung cancer (aNSCLC), several clinical factors have been associated with prognosis in the context of the immunotherapy. Among them, female gender was proposed as negative factor for immuno-checkpoint inhibitors (ICI); however its independent impact of other prognostic factors (i.e., PS, smoking or biological parameters, etc) remains unclear. We assessed whether the female gender correlates with ICI-outcomes in patients with aNSCLC treated upfront with ICI-alone or combined to chemotherapy (CT).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
